Ultivue Announces Co-Marketing Agreement with Fluidigm for Biomarker Imaging Solutions for Precision Medicine
August 05 2021 - 9:30AM
Business Wire
Ultivue, Inc. and Fluidigm Corporation (Nasdaq:FLDM) today
announced a co-marketing agreement in which the companies will
offer customers a comprehensive portfolio of workflow solutions for
biomarker discovery and drug development.
Ultivue, a leader in advancing precision medicine solutions by
accelerating tissue biomarker discovery and validation develops
unique assays for use in multiplex immunofluorescence imaging and
analysis. Its proprietary InSituPlex® technology is designed for
fast and comprehensive exploration of biologically-relevant markers
combined with same slide-H&E analysis in precious tissue
samples.
Fluidigm is a leader in high-parameter imaging for the clinical
translational research and clinical testing markets. It’s Imaging
Mass Cytometry™ (IMC™) technology is designed for highly
multiplexed targeted interrogation of tissue sections for 40 or
more protein markers in one scan, with distinct non-overlapping
signals from element-labeled antibodies detected simultaneously for
each sub-micrometer pixel.
The collaboration provides reseachers with end-to-end service
capability for clinical and translational work. For example,
InSituPlex technology is well suited to identify regions of
interest that may require downstream, deep profiling with IMC™.
Customer access to both technologies can improve the efficiency of
drug discovery programs and, in translational research, enable
patient stratification to triage cases that require further
investigation.
“Imaging Mass Cytometry has become integral to the clinical
translational research and clinical testing markets,” said Chris
Linthwaite, Fluidigm President and CEO. “Through Fluidigm
Therapeutic Insights Services, we will offer our customers access
to our technology as well as that of Ultivue, providing optimum
imaging solutions for biomarker discovery and drug
development.”
“Ultivue is at the forefront of innovation to provide unique
biological insights for our customers,” said Mark Rees,
Vice-President of Business Development at Ultivue. “Our InSituPlex®
technology offers valuable profiling of the tissue and expands the
depth of information possible from a single section that is
complementary to the high-parameter capabilities of Imaging Mass
Cytometry. We believe this joint offering with Fluidigm will now
provide researchers a seamless workflow enabling a far more
efficient biomarker discovery and drug development process.”
About Fluidigm
Fluidigm Corporation (Nasdaq:FLDM) focuses on the most pressing
needs in translational and clinical research, including cancer,
immunology, and immunotherapy. Using proprietary CyTOF® and
microfluidics technologies, we develop, manufacture, and market
multi-omic solutions to drive meaningful insights in health and
disease, identify biomarkers to inform decisions, and accelerate
the development of more effective therapies. Our customers are
leading academic, government, pharmaceutical, biotechnology, plant
and animal research, and clinical laboratories worldwide. Together
with them, we strive to increase the quality of life for all.
Fluidigm, the Fluidigm logo, and CyTOF are trademarks and/or
registered trademarks of Fluidigm Corporation in the United States
and/or other countries. All other trademarks are the sole property
of their respective owners. For Research Use Only. Not for use in
diagnostic procedures. For more information, visit
fluidigm.com.
About Ultivue
Ultivue, Inc. provides researchers and scientists with multiplex
biomarker assays for tissue phenotyping and digital pathology. Its
proprietary InSituPlex® technology enables advanced exploration and
interrogation of tissue samples for precision medicine research.
These highly customizable solutions and scientific consultative
approach strengthen and accelerate biomarker discovery and drug
development programs. For more information, visit ultivue.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210805005443/en/
Ultivue Mark Rees, PhD Vice President Corporate
Development (+1) 516-512-4977 mark.rees@ultivue.com Fluidigm
Mark Spearman Senior Director, Corporate Communications (+1)
650-243-6621 mark.spearman@fluidigm.com
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Apr 2023 to Apr 2024